Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Idiopathic (Essential) Hypertension - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Idiopathic (Essential) Hypertension - Pipeline Review, H1 2016', provides an overview of the Idiopathic (Essential) Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic (Essential) Hypertension and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension - The report reviews pipeline therapeutics for Idiopathic (Essential) Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Idiopathic (Essential) Hypertension therapeutics and enlists all their major and minor projects - The report assesses Idiopathic (Essential) Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Idiopathic (Essential) Hypertension Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Idiopathic (Essential) Hypertension Overview 8 Therapeutics Development 9 Pipeline Products for Idiopathic (Essential) Hypertension - Overview 9 Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies 10 Idiopathic (Essential) Hypertension - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Idiopathic (Essential) Hypertension - Products under Development by Companies 14 Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development 15 Actelion Ltd 15 Bayer AG 16 Chong Kun Dang Pharmaceutical Corp. 17 Daiichi Sankyo Company, Limited 18 Eli Lilly and Company 19 HanAll Biopharma Co., Ltd. 20 Innopharmax Inc. 21 Lee's Pharmaceutical Holdings Limited 22 PhaseBio Pharmaceuticals, Inc. 23 Quantum Genomics SA 24 Sun Pharma Advanced Research Company Ltd. 25 Takeda Pharmaceutical Company Limited 26 Idiopathic (Essential) Hypertension - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Combination Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 (amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 (amlodipine besylate + candesartan cilexetil) - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 (amlodipine besylate + hydrochlorothiazide + losartan potassium) - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 (atorvastatin calcium + losartan potassium) - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 (candesartan cilexetil + nifedipine) - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 azilsartan medoxomil - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 carvedilol phosphate CR - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 carvedilol phosphate SR - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 CS-3150 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 lisinopril - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 LY-2623091 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 PB-1046 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 PB-1120 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 QGC-001 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 rostafuroxin - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Small Molecule to Antagonize Endothelin Receptor A and Endothelin Receptor B for Essential Hypertension - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Idiopathic (Essential) Hypertension - Recent Pipeline Updates 58 Idiopathic (Essential) Hypertension - Dormant Projects 64 Idiopathic (Essential) Hypertension - Product Development Milestones 65 Featured News & Press Releases 65 Oct 06, 2015: Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure 65 Jun 12, 2013: Lee's Pharma Enrolls First Patient In Phase IIb Clinical Trial Of Rostafuroxin In Italy 65 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 67 Disclaimer 68
List of Tables
Number of Products under Development for Idiopathic (Essential) Hypertension, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Idiopathic (Essential) Hypertension - Pipeline by Actelion Ltd, H1 2016 15 Idiopathic (Essential) Hypertension - Pipeline by Bayer AG, H1 2016 16 Idiopathic (Essential) Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 17 Idiopathic (Essential) Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 18 Idiopathic (Essential) Hypertension - Pipeline by Eli Lilly and Company, H1 2016 19 Idiopathic (Essential) Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 20 Idiopathic (Essential) Hypertension - Pipeline by Innopharmax Inc., H1 2016 21 Idiopathic (Essential) Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 22 Idiopathic (Essential) Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016 23 Idiopathic (Essential) Hypertension - Pipeline by Quantum Genomics SA, H1 2016 24 Idiopathic (Essential) Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 25 Idiopathic (Essential) Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 26 Assessment by Monotherapy Products, H1 2016 27 Assessment by Combination Products, H1 2016 28 Number of Products by Stage and Target, H1 2016 30 Number of Products by Stage and Mechanism of Action, H1 2016 32 Number of Products by Stage and Route of Administration, H1 2016 34 Number of Products by Stage and Molecule Type, H1 2016 36 Idiopathic (Essential) Hypertension Therapeutics - Recent Pipeline Updates, H1 2016 58 Idiopathic (Essential) Hypertension - Dormant Projects, H1 2016 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
